I reviewed ACCENT phase 1b related announcements, and I think the poster presentation published for "American Association of Cancer Research Annual Meeting 2024" provides helpful details about the that phase.
As can be seen, the overall response rate has been 43%, but the rate for the 400 mg dosage has been way higher, ranging from 100% to 57% depending on whether or not cases that decreased from 400 mg to lower doses are included."
Ann: Additional Patient Response in Pancreatic Cancer Trial, page-21
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $28.85M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $11.72K | 111.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 157497 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |